Nov 19, 2010 by Brian Orelli, PhDUp 95%, but Still Risky as HeckThat's an understatement for MELA Sciences.
Nov 17, 2010 by Brian Orelli, PhDLet's Wait for the 30,000-Patient TrialMerck shouldn't pop the Champagne just yet.
Nov 17, 2010 by Brian Orelli, PhD52 Years Down, 1 Month to GoLupus treatment Benlysta moves closer to approval.
Nov 16, 2010 by Brian Orelli, PhDWell, That Just StinksGlaxo's Lovaza doesn't fix heart rhythm problems.
Nov 12, 2010 by Brian Orelli, PhDBenlysta: Not Perfect, but Good EnoughHuman Genome should get past the FDA advisory panel next week.
Nov 11, 2010 by Brian Orelli, PhDModerate Results, Moderate Rally for DendreonSometimes good enough really is good enough.
Nov 11, 2010 by Brian Orelli, PhDATTRACTing Clinical Trial FailureLet's not make it a habit, Novartis.
Nov 9, 2010 by Brian Orelli, PhDArena Pharmaceuticals Scores Some PointsBut it's still way behind in the game.
Nov 9, 2010 by Brian Orelli, PhDForget R&D; Buy Your Way Into DiagnosticsThat seems to be Eli Lilly's approach.
Nov 8, 2010 by Brian Orelli, PhDNo Sticking Point Here: Pfizer's Potential Blockbuster WorksOne phase 3 down, four to go.
Nov 5, 2010 by Brian Orelli, PhDBetter Late Than Never for CymbaltaEli Lilly gets an expanded approval for Cymbalta.
Nov 3, 2010 by Brian Orelli, PhDTeva's New Drugs Pay OffThe generic-drug maker keeps generating big profits.
Nov 3, 2010 by Brian Orelli, PhDA Generic Prescription for Double-Digit GrowthMedcoHealth Solutions has it.
Nov 1, 2010 by Brian Orelli, PhDStock Doubles! No Crying HereAVANIR gets its long-awaited FDA approval.
